Boehringer Ingelheim has posted net sales of €6.4 billion in the first six months of 2011 resulting in a 4% growth when compared to the same period the year before.
Sales were boosted by the new launches of the anticoagulant Pradaxa and diabetes treatments Twynsta and Tradjenta which accounted for 60% of revenue.
Professor Andreas Barner, Chairman of the Board of Managing Directors, says Boehringer’s Value through Innovation vision “proves itself sustainably as the basis of our company.”
Overall, prescription medicines net sales amassed €4.9 billion in the first half of 2011 and turnover of the Consumer Healthcare Business was up 11% to €667 million.
Following strong sales in emerging markets, the company’s Human Pharmaceuticals’ net sales increased by 12% to €890 million.
“For Boehringer Ingelheim the first half of business year 2011 is characterised in turnover terms by successful new launches,” said Hubertus von Baumbach, Member of the Board of Managing Directors responsible for Finance.
“A good earnings position overall has enabled us to activate again higher investment in research and development, even though further burdensome interventions by the legislators in price-setting for prescription medicines have had a negative effect.”
Pradaxa, a novel, direct thrombin inhibitor was approved across Europe for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Outside of the EU, it has already been granted approval in the USA, Canada, Japan and other countries on four continents.
Professor Barner also added that several new substances from the company’s own research and development had made further progress and a number of new biological and chemical active ingredients were transferred from the preclinical stage to clinical development.